Since almost all 1p/19q-co-deleted oligodendrogliomas demonstrate concurrent G-CIMP and MGMT promoter methylation, G-CIMP could serve as a molecular classifier for IDH-mutant subgroups, and MGMT methylation status may provide actionable guidance for chemotherapy selection, exemplifying the translational synergy between these epigenetic biomarkers [6]. This evidence concerns the gene MGMT and oligodendroglioma.